Central Serous ChorioretinopathyMIND'S EYENCT07767058
Mindfulness for Central Serous Chorioretinopathy
A study testing Mindfulness in people with Central Serous Chorioretinopathy, run by King's College Hospital NHS Trust at 6 sites in United Kingdom.
Trial summary
The primary goal of this clinical trial is to test whether a mindfulness-based treatment is effective at shortening the duration of, and improving the features of, central serous chorioretinopathy in adults. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Central Serous Chorioretinopathy
- What is being tested?
- Mindfulness
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 6 sitesUnited Kingdom
- Study dates
- 1 Oct 2026to 31 Jul 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- CSCR Cases:
- Adults (> 18 years old)
- Active fovea-involving CSCR
- Both of the following major diagnostic criteria*:
- Presence of SRF within the central 1mm subfield (circular zone of 1mm diameter centred on the foveal umbo) on OCT scan
- At least 1 area of RPE alteration on fundus autofluorescence, OCT or infrared imaging
Show all 19Show fewer
- Any one of the following minor diagnostic criteria*:
- Sub-foveal choroidal thickness ≥ 400 µm on OCT
- ≥ 1 focal leak on FFA
- Mid-phase hyperfluorescent placoid areas on ICGA
- First episode or a distinct recurrent episode
- Duration of current episode < 180 days
- No other cause for the above findings (e.g. diabetic retinopathy, exudative age-related macular degeneration, or polypoidal choroidal vasculopathy)
- Inclusion criteria based on the Central Serous Chorioretinopathy International Group diagnostic criteria for idiopathic CSCR.13 According to these criteria, an FFA and ICG are not required for diagnosis if choroidal thickness on OCT is ≥ 400 µm. Therefore, review OCT before performing FFA and/or ICGA.
- Non-CSCR Cases:
- Adults (> 18 years old)
- Approximately age- and sex-matched to CSCR cases
- No CSCR
- No other BCVA-affecting ocular disease or condition
Who cannot join
- Study eye:
- Any treatment for current or previous CSCR with PDT or laser
- Use of any topical medication for CSCR currently, or in the last 90 days
- Use of topical steroids or carbonic anhydrase inhibitors currently, or in the last 90 days
- Intraocular anti-VEGF therapy in the last 180 days
- Intraocular steroids in the last 180 days or intraocular steroid implant in the last 3 years
Show all 23Show fewer
- Treatment with retinal or macular laser at any point (except peripheral laser retinopexy at least 90 days prior)
- Cryotherapy within 90 days
- Previous cyclodiode therapy at any point
- Laser refractive surgery within 90 days
- Intraocular surgery within 90 days
- Presence of any other disease that could cause retinal or SRF (e.g. diabetic retinopathy, exudative age-related macular degeneration, or polypoidal choroidal vasculopathy)
- Current or prior retinal or choroidal neovascularisation of any cause
- Diabetic retinopathy
- Presence of any other disease which is thought to be currently affecting BCVA, or likely to do so during study participation
- Media opacity precluding fundus examination and/or imaging (e.g. dense cataract)
- General:
- Current, recent (within 90 days) or anticipated (during study participation) treatment with systemic anti-VEGF therapy, oral/intravenous/intramuscular steroids, systemic carbonic anhydrase inhibitors or systemic hormone therapy (except hormonal contraception)
- Current or recent (within 90 days) practice of regular (more than twice per week) meditation or mindfulness
- Unable, unwilling or unlikely to undertake study activities
- Any condition which, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol, such as dementia, mental illness, or serious systemic medical disease
- Where potential CSCR participants present with both eyes meeting the above criteria, one eye only will be included in the study. The eye with the greatest central 1 mm subfield thickness (µm) on OCT imaging will be the study eye. In these participants, data on the fellow affected eye in the study will still be collected, to allow the possibility of looking at the symmetry of outcomes between eyes of an individual but will not be included in formal statistical analysis.
- For non-CSCR participants, only one eye will be included in the study. Where potential non-CSCR participants present with both eyes meeting the above criteria, the study eye will be chosen at random by last digit of their day of birth, with even numbers including 0 corresponding to right eye and odd numbers corresponding to left eye (e.g. DOB 31/12/1960 = left eye).
Trial locations and contacts
6 sites in 1 country. Contact the study team or a site near you to ask about taking part.
King's Ophthalmology Research Unit contact
6 sites in 1 country
United Kingdom6 sites
Bristol Eye Hospital
Bristol, BS1 2LX
Eleanor Hiscott, 01173424770, Eleanor.Hiscott@uhbw.nhs.uk
Clinical Research Unit Manager, BEHCRUManagers@uhbw.nhs.uk
Kent and Canterbury Hospital
Canterbury, CT1 3NG
Amy Kenyon, 01227783172, amykenyon@nhs.net
Caroline Cowley, ekhuft.researchandinnovation@nhs.net
Clinical Eye Research Centre, St Paul's Eye Unit, Liverpool University Hospitals NHS Trust
Liverpool, L7 8YE
Florina Caban, 01517063798, florina.caban@liverpoolft.nhs.uk
Ian Pearce, ian.pearce@liverpoolft.nhs.uk
King's College London Frost Eye Departent, Guys' and St Thomas' Hospital
London, SE1 7EH
Humra Chadwick, 02071884885, humra.chadwick1@nhs.net
Vivi Riga
King's College Hospital
London, SE5 9RS
Trial Manager, 02032997791, kch-tr.ophthalmologyresearch@nhs.net
Lisa Ramazzotto, lisa.ramazzotto@nhs.net
Hillingdon Hospital
London, UB8 3NN
Kash Khuttan, 07930550860, kash.khuttan@nhs.net
Samantha Kon, s.kon@nhs.net
About this study
Official title: A Pilot Randomised Controlled Trial of a Disease-specific Mindfulness-based Therapy for Central Serous Chorioretinopathy
The primary goal of this clinical trial is to test whether a mindfulness-based treatment is effective at shortening the duration of, and improving the features of, central serous chorioretinopathy in adults. Researchers will compare adults with central serous chorioretinopathy who undertake an 8 week mindfulness-based treatment course, with those who do no mindfulness, to see if mindfulness improves time to disease resolution and disease features.
The secondary goal of this clinical trial is to compare adults with central serous chorioretinopathy to adults with healthy eyes across a variety of stress-related factors, and also measure the change in some of these factors, if any, caused by mindfulness.
Read more
The questions this clinical trial aims to answer are:
- is mindfulness effective at improving the clinical course of central serous chorioretinopathy?
- is a mindfulness-based treatment programme for central serous chorioretinopathy acceptable to adults with the disease?
- if effective, does mindfulness alter any stress-related psychological or biological features in adults with central serous chorioretinopathy?
- what are the stress-related psychological and biological features of adults with central serous chorioretinopathy, compared to adults with healthy eyes?
Participants will:
- Undertake daily mindfulness practices for 8 weeks and participate in fortnightly group sessions, or undertake no mindfulness
- Visit the research clinic once every month for the first six months, and then again at 12 months, for checkups and tests
- Conditions
- Central Serous Chorioretinopathy
- Being tested
- Mindfulness
- Keywords
- central serous chorioretinopathy, mindfulness, pilot clinical trial, stress
- Medical subject headings
- Central Serous Chorioretinopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MindfulnessBehavioural
The intervention is an 8 week course of daily mindfulness practices, accompanied by 6 months of fortnightly group sessions. Two introductory videos will explain about central serous chorioretinopathy, mindfulness and the links both have to stress-related factors, and outline the structure of the mindfulness course. Participants will be given a set of video and audio files that will guide them through daily mindfulness practices, for a total duration of 8 weeks. Daily practices will include body scan exercises, breathing exercises, mindful movement, mindful moments in daily life exercises, and mindfulness in response to stress exercises. Individual practices will range from 5 - 20 minutes' duration. There will also be fortnightly group mindfulness sessions, facilitated by a mindfulness coach and with an Ophthalmologist present. They will include guided mindfulness practices and free discussion time for participants to share their experience of the intervention and ask questions.
| Study group | Role | What they receive |
|---|---|---|
| Mindfulness | Experimental | The intervention consists of consists of an 8-week self-directed daily mindfulness course, combined with fortnightly group mindfulness sessions that participants are encouraged to join from enrolment up until their month 6 follow up visit. The intervention has been designed specifically for this trial and is tailored to central serous chorioretinopathy.
Participants will be given a set of video and audio guidance for daily mindfulness-based practices, for a total duration of 8 weeks, alongside a 'road map' of the intervention to prompt them to which practices to use on each day. Daily practices will include body scan exercises, breathing exercises, mindful movement, mindful moments in daily life exercises, and mindfulness in response to stress exercises. Practices will range from 5 - 20 minutes' duration. Participants will be invited to join fortnightly group mindfulness calls, held via Microsoft Teams, for the first six months of their involvement in the trial. Receives: Behavioral: Mindfulness |
| No mindfulness | No intervention | This is the control group. They will not undertake daily mindfulness practices or fortnightly group sessions. |
| No central serous chorioretinopathy (healthy eyes) | No intervention | This arm is the case-control comparator, consisting of age- and sex-matched adults with no central serous chorioretinopathy or other sight-threatening eye conditions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to disease resolution (days), defined as the absence of foveal centrepoint subretinal fluid (SRF) on optical coherence tomography (OCT) imaging, without treatment with either photodynamic therapy (PDT) or laser.
Measured: From enrolment until 6 months
Secondary outcomes (36)
Change in best corrected visual acuity (Early Treatment Diabetic Retinopathy Study [ETDRS] letter score)
Measured: From baseline to month 2, 6 and 12
Change in 'real world' visual acuity (VA; ETDRS letter score), measured with the patient's usual refractive correction
Measured: From baseline to month 2, 6 and 12
Change in low luminance visual acuity (ETDRS letter score)
Measured: From baseline to month 2, 6 and 12
Change in maximum subretinal fluid (SRF) height (µm) at any given macular location
Measured: From baseline to month 2, 6 and 12
Change in central 1mm subfield thickness (µm)
Measured: From baseline to month 2, 6 and 12
Area under the curve of 'real world' VA (ETDRS letter score)
Measured: From baseline to month 12
Area under curve of maximum SRF height (µm) at any given macular location
Measured: From baseline to month 12
Area under the curve of central 1 mm subfield thickness (µm)
Measured: From baseline to month 12
Disease resolution, as defined in the primary outcome (%)
Measured: From baseline to month 2, 6 and 12
Treatment of central serous chorioretinopathy (CSCR) with either photodynamic therapy (PDT) or laser (%)
Measured: From baseline to month 6 and 12
Re-emergence of CSCR (defined as in the inclusion criteria) in those achieving the primary outcome (%)
Measured: From baseline to month 6 and 12
Change in Perceived Stress Questionnaire Index (PSQ Index score; composite score)
30 item questionnaire. Raw score first calculated. (Raw score - 30) / 90 = PSQ Index (always a value between 0 and 1). Higher scores indicate higher levels of perceived stress.
Measured: From baseline to month 2, 6 and 12
Change in Global Pittsburgh Sleep Quality Index Score (PSQI; composite score)
19 item questionnaire. Score range 0 - 21; 0 = good sleep quality; score > 5 is standardised clinical threshold for poor sleep quality.
Measured: From baseline to month 2, 6 and 12
Change in Patient Health Questionnaire-9 score (PHQ-9; composite score)
9 item questionnaire. Score range 0 - 27; severity of depressive symptoms: 0-4 (Minimal), 5-9 (Mild), 10-14 (Moderate), 15-19 (Moderately Severe), and 20-27 (Severe).
Measured: From baseline to month 2, 6 and 12
Change in Generalised Anxiety Disorder-7 score (GAD-7; composite score)
7 item questionnaire. Score range 0 - 21; 0-4 Minimal anxiety, 5-9 Mild anxiety, 10-14 Moderate anxiety, 15-21 Severe anxiety.
Measured: From baseline to month 2, 6 and 12
Change in serum total cholesterol (mmol/L)
Measured: From baseline to month 2
Change in serum pre-10am cortisol (nmol/L)
Measured: From baseline to month 2
Change in serum testosterone (nmol/L)
Measured: From baseline to month 2
Change in serum progesterone (nmol/L)
Measured: From baseline to month 2
Change in serum oestradiol (pmol/L)
Measured: From baseline to month 2
Change in serum follicle stimulating hormone (FSH; IU/L)
Measured: From baseline to month 2
Change in serum luteinising hormone (LH; IU/L)
Measured: From baseline to month 2
Change in serum angiotensin converting enzyme (ACE; U/L)
Measured: From baseline to month 2
Change in urine 24-hour cortisol (nmol/24hr)
Measured: From baseline to month 2
Change in urine serotonin (µg/g Crea)
Measured: From baseline to month 2
Change in urine dopamine (µg/g Crea)
Measured: From baseline to month 2
Change in urine noradrenaline (NA; µg/g Crea)
Measured: From baseline to month 2
Change in urine adrenaline (Adr; µg/g Crea)
Measured: From baseline to month 2
Change in urine NA/Adr ratio
Measured: From baseline to month 2
Area under the curve of saliva cortisol awakening response (ng/ml)
Saliva cortisol awakening response is measured with four samples of saliva taken immediately upon waking, and 15/30/60 after waking.
Measured: From baseline to month 2
Area under the curve of saliva cortisol diurnal variation (ng/ml)
Saliva diurnal variation is measured with four saliva samples, taken at 60 minutes after waking, 12pm, 4pm and 8pm.
Measured: From baseline to month 2
Change in systolic blood pressure (mmHg)
Measured: From baseline to month 2
Change in diastolic blood pressure (mmHg)
Measured: From baseline to month 2
Change in maximum choroidal thickness (µm) at any given macular location
Measured: From baseline to month 2
Area under the curve of maximum choroidal thickness (µm) at any given macular location
Measured: From baseline to month 12
Change in National Eye Institute Visual Function Questionnaire-25 score (VFQ-25; composite score)
25 item questionnaire. Score range 0 - 100. Higher scores indicate better visual function.
Measured: From baseline to month 2, 6 and 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2026
- Study start1 Oct 2026 (estimated)
- Primary completion31 Jul 2030 (estimated)
- Study completion31 Jul 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Central Serous ChorioretinopathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This trial contains two models - an interventional model and a case-control model. The primary model is a parallel interventional model involving two arms (intervention and control) of participants, both of which have central serous chorioretinopathy. The secondary model is a case control model involving the two groups of participants with central serous chorioretinopathy, and another group of participants with healthy eyes. As such, the investigators have entered 3 total arms to the trial in the section below, but only two of these arms are part of the interventional element of the trial.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King's College Hospital NHS Trust
- Sponsor type
- University, hospital or other
- Collaborators
- King's College London
- Responsible party
- Sponsor
- Investigators
- Timothy Jackson, Principal investigator, King's College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07767058
- Sponsor's protocol ID
- IRAS 374706
- Acronym
- MIND'S EYE
- Status last verified
- Jul 2026
- First submitted
- 15 Jul 2026
- Last updated
- 28 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot Randomised Controlled Trial of a Disease-specific Mindfulness-based Therapy for Central Serous Chorioretinopathy
- ClinicalTrials.gov ID
- NCT07767058
- Acronym / sponsor ID
- MIND'S EYE / IRAS 374706
- Conditions
- Central Serous Chorioretinopathy
- Keywords
- central serous chorioretinopathy, mindfulness, pilot clinical trial, stress
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- King's College Hospital NHS TrustUniversity, hospital or other
- Collaborators
- King's College London
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 31 Jul 2030 (estimated)
- Study completion
- 31 Jul 2030 (estimated)
- First posted
- 17 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary goal of this clinical trial is to test whether a mindfulness-based treatment is effective at shortening the duration of, and improving the features of, central serous chorioretinopathy in adults. Researchers will compare adults with central serous chorioretinopathy who undertake an 8 week mindfulness-based treatment course, with those who do no mindfulness, to see if mindfulness improves time to disease resolution and disease features.
The secondary goal of this clinical trial is to compare adults with central serous chorioretinopathy to adults with healthy eyes across a variety of stress-related factors, and also measure the change in some of these factors, if any, caused by mindfulness.
The questions this clinical trial aims to answer are:
- is mindfulness effective at improving the clinical course of central serous chorioretinopathy?
- is a mindfulness-based treatment programme for central serous chorioretinopathy acceptable to adults with the disease?
- if effective, does mindfulness alter any stress-related psychological or biological features in adults with central serous chorioretinopathy?
- what are the stress-related psychological and biological features of adults with central serous chorioretinopathy, compared to adults with healthy eyes?
Participants will:
- Undertake daily mindfulness practices for 8 weeks and participate in fortnightly group sessions, or undertake no mindfulness
- Visit the research clinic once every month for the first six months, and then again at 12 months, for checkups and tests
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- This trial contains two models - an interventional model and a case-control model. The primary model is a parallel interventional model involving two arms (intervention and control) of participants, both of which have central serous chorioretinopathy. The secondary model is a case control model involving the two groups of participants with central serous chorioretinopathy, and another group of participants with healthy eyes. As such, the investigators have entered 3 total arms to the trial in the section below, but only two of these arms are part of the interventional element of the trial.
| Arm | Type | Receives |
|---|---|---|
| Mindfulness | Experimental | Behavioral: MindfulnessThe intervention consists of consists of an 8-week self-directed daily mindfulness course, combined with fortnightly group mindfulness sessions that participants are encouraged to join from enrolment up until their month 6 follow up visit. The intervention has been designed specifically for this trial and is tailored to central serous chorioretinopathy. Participants will be given a set of video and audio guidance for daily mindfulness-based practices, for a total duration of 8 weeks, alongside a 'road map' of the intervention to prompt them to which practices to use on each day. Daily practices will include body scan exercises, breathing exercises, mindful movement, mindful moments in daily life exercises, and mindfulness in response to stress exercises. Practices will range from 5 - 20 minutes' duration. Participants will be invited to join fortnightly group mindfulness calls, held via Microsoft Teams, for the first six months of their involvement in the trial. |
| No mindfulness | No intervention | –This is the control group. They will not undertake daily mindfulness practices or fortnightly group sessions. |
| No central serous chorioretinopathy (healthy eyes) | No intervention | –This arm is the case-control comparator, consisting of age- and sex-matched adults with no central serous chorioretinopathy or other sight-threatening eye conditions |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (19 listed)
- Adults (> 18 years old)
- Active fovea-involving CSCR
- Both of the following major diagnostic criteria*:
- Any one of the following minor diagnostic criteria*:
- First episode or a distinct recurrent episode
Key exclusion criteria (23 listed)
- Any treatment for current or previous CSCR with PDT or laser
- Use of any topical medication for CSCR currently, or in the last 90 days
- Use of topical steroids or carbonic anhydrase inhibitors currently, or in the last 90 days
- Intraocular anti-VEGF therapy in the last 180 days
- Intraocular steroids in the last 180 days or intraocular steroid implant in the last 3 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MindfulnessThe intervention is an 8 week course of daily mindfulness practices, accompanied by 6 months of fortnightly group sessions. Two introductory videos will explain about central serous chorioretinopathy, mindfulness and the links both have to stress-related factors, and outline the structure of the mindfulness course. Participants will be given a set of video and audio files that will guide them through daily mindfulness practices, for a total duration of 8 weeks. Daily practices will include body scan exercises, breathing exercises, mindful movement, mindful moments in daily life exercises, and mindfulness in response to stress exercises. Individual practices will range from 5 - 20 minutes' duration. There will also be fortnightly group mindfulness sessions, facilitated by a mindfulness coach and with an Ophthalmologist present. They will include guided mindfulness practices and free discussion time for participants to share their experience of the intervention and ask questions. | Behavioural | Mindfulness |
Primary outcome
Time to disease resolution (days), defined as the absence of foveal centrepoint subretinal fluid (SRF) on optical coherence tomography (OCT) imaging, without treatment with either photodynamic therapy (PDT) or laser.
Time frame: From enrolment until 6 months
36 secondary outcomes
Change in best corrected visual acuity (Early Treatment Diabetic Retinopathy Study [ETDRS] letter score)
Time frame: From baseline to month 2, 6 and 12
Change in 'real world' visual acuity (VA; ETDRS letter score), measured with the patient's usual refractive correction
Time frame: From baseline to month 2, 6 and 12
Change in low luminance visual acuity (ETDRS letter score)
Time frame: From baseline to month 2, 6 and 12
Change in maximum subretinal fluid (SRF) height (µm) at any given macular location
Time frame: From baseline to month 2, 6 and 12
Change in central 1mm subfield thickness (µm)
Time frame: From baseline to month 2, 6 and 12
Area under the curve of 'real world' VA (ETDRS letter score)
Time frame: From baseline to month 12
Area under curve of maximum SRF height (µm) at any given macular location
Time frame: From baseline to month 12
Area under the curve of central 1 mm subfield thickness (µm)
Time frame: From baseline to month 12
Disease resolution, as defined in the primary outcome (%)
Time frame: From baseline to month 2, 6 and 12
Treatment of central serous chorioretinopathy (CSCR) with either photodynamic therapy (PDT) or laser (%)
Time frame: From baseline to month 6 and 12
Re-emergence of CSCR (defined as in the inclusion criteria) in those achieving the primary outcome (%)
Time frame: From baseline to month 6 and 12
Change in Perceived Stress Questionnaire Index (PSQ Index score; composite score)
Time frame: From baseline to month 2, 6 and 12
Change in Global Pittsburgh Sleep Quality Index Score (PSQI; composite score)
Time frame: From baseline to month 2, 6 and 12
Change in Patient Health Questionnaire-9 score (PHQ-9; composite score)
Time frame: From baseline to month 2, 6 and 12
Change in Generalised Anxiety Disorder-7 score (GAD-7; composite score)
Time frame: From baseline to month 2, 6 and 12
Change in serum total cholesterol (mmol/L)
Time frame: From baseline to month 2
Change in serum pre-10am cortisol (nmol/L)
Time frame: From baseline to month 2
Change in serum testosterone (nmol/L)
Time frame: From baseline to month 2
Change in serum progesterone (nmol/L)
Time frame: From baseline to month 2
Change in serum oestradiol (pmol/L)
Time frame: From baseline to month 2
Change in serum follicle stimulating hormone (FSH; IU/L)
Time frame: From baseline to month 2
Change in serum luteinising hormone (LH; IU/L)
Time frame: From baseline to month 2
Change in serum angiotensin converting enzyme (ACE; U/L)
Time frame: From baseline to month 2
Change in urine 24-hour cortisol (nmol/24hr)
Time frame: From baseline to month 2
Change in urine serotonin (µg/g Crea)
Time frame: From baseline to month 2
Change in urine dopamine (µg/g Crea)
Time frame: From baseline to month 2
Change in urine noradrenaline (NA; µg/g Crea)
Time frame: From baseline to month 2
Change in urine adrenaline (Adr; µg/g Crea)
Time frame: From baseline to month 2
Change in urine NA/Adr ratio
Time frame: From baseline to month 2
Area under the curve of saliva cortisol awakening response (ng/ml)
Time frame: From baseline to month 2
Area under the curve of saliva cortisol diurnal variation (ng/ml)
Time frame: From baseline to month 2
Change in systolic blood pressure (mmHg)
Time frame: From baseline to month 2
Change in diastolic blood pressure (mmHg)
Time frame: From baseline to month 2
Change in maximum choroidal thickness (µm) at any given macular location
Time frame: From baseline to month 2
Area under the curve of maximum choroidal thickness (µm) at any given macular location
Time frame: From baseline to month 12
Change in National Eye Institute Visual Function Questionnaire-25 score (VFQ-25; composite score)
Time frame: From baseline to month 2, 6 and 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Central Serous Chorioretinopathy
Not yet recruitingObservational study
A Case-Control Study Revealing Intraocular Microenvironment Characteristics in Patients With Ocular Diseases Based on Multi-Omics Analysis
Age- Related Macular Degeneration, Diabetic Retinopathy
RecruitingObservational study
Biomarkers and Choroidal Neovascularization
Choroidal Neovascularization, Mineralocorticoid Excess
Not yet recruitingPhase 2
Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial
Central Serous Chorioretinopathy (CSC)
Recruiting
the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Not yet recruitingObservational study
Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients
Central Serous Chorioretinopathy (CSC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
King's Ophthalmology Research Unit contact
Timothy Jackson principal investigator
King's College London
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mindfulness in people with Central Serous Chorioretinopathy, run by King's College Hospital NHS Trust at 6 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Olivia Cundy, BA, BMBCh (02032997791, olivia.cundy@nhs.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to disease resolution (days), defined as the absence of foveal centrepoint subretinal fluid (SRF) on optical coherence tomography (OCT) imaging, without treatment with either photodynamic therapy (PDT) or laser. (time frame: From enrolment until 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2026.